Cancer Research UK and NCI to kick off next rounds of Grand Challenges

Nicole DeFeudis

Editor

Over the last five years, Cancer Research UK has splashed £130 million ($172.6 million) into global oncology research through its Grand Challenge initiative. And there’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Cancer Research UK and NCI to kick off next rounds of Grand Challenges

Nicole DeFeudis

Editor

Sign up to read this article for free.

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

Advocacy groups and experts call for decade-long ban on germline editing

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M

CRISPR patent spat revived by federal appeals court ruling

Can­cer Re­search UK and NCI to kick off next rounds of Grand Chal­lenges

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

SK, Car­lyle bol­ster blue­bird bio bid; Theri­ni Bio rais­es $39M

CRISPR patent spat re­vived by fed­er­al ap­peals court rul­ing

Cancer Research UK and NCI to kick off next rounds of Grand Challenges

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

Advocacy groups and experts call for decade-long ban on germline editing

SK, Carlyle bolster bluebird bio bid; Therini Bio raises $39M

CRISPR patent spat revived by federal appeals court ruling